Skip to main content
Caplight Logo









De Novo Biotherapeutics

De Novo Biotherapeutics

Private
SeoulHealthcare & Life Scienceshttps://denovobio.co.kr/en/index.php

Last Round

Series A

Nov 25, 2022

Total Funding Raised

$9.99M

Company Overview

De Novo Biotherapeutics is a biotechnology company that develops mRNA-encoded, NK cell-engaging bi- or multi-specific antibodies for the treatment of relapsed or refractory cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

mRNA therapeuticslipid nanoparticleLNPimmuno-oncologyNK cell therapybi-specific antibodiesmulti-specific antibodiesin vivo productiondrug delivery platformcancer immunotherapybiotech drug discoverynext-gen biologicsprecision medicinebiopharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

De Novo Biotherapeutics Comparables

Compare De Novo Biotherapeutics with similar companies based on industry and business-model similarity.

De Novo Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CREATE Medicines
81%
Therorna Inc.
81%
Eli Lilly and Company
78%

De Novo Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 25, 2022
SeedOct 21, 2021

De Novo Biotherapeutics Investors

Notable investors and investment history

De Novo Biotherapeutics investors
InvestorRounds
Stonebridge VenturesSeries A
Heungkuk SecuritiesSeries A
Atinum InvestmentSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 25, 2022

    Raised $6M from Heungkuk Securities, Atinum Investment, and Stonebridge Ventures.

  • Oct 21, 2021

    $4.24M round completed.

De Novo Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

De Novo Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about De Novo Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Year Founded2021
Last FundingNov 25, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?